{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:13:21Z","timestamp":1794014001352,"version":"4.8.0"},"reference-count":102,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,9,12]]},"abstract":"<jats:sec id=\"ab-jrv230015-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Ulcerative colitis (UC) is a chronic inflammatory condition of the colon, with a prevalence exceeding 400 per 100\u202f000 in North America. Individuals with UC have a lower life expectancy and are at increased risk for colectomy and colorectal cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv230015-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>UC impairs quality of life secondary to inflammation of the colon causing chronic diarrhea and rectal bleeding. Extraintestinal manifestations, such as primary sclerosing cholangitis, occur in approximately 27% of patients with UC. People with UC require monitoring of symptoms and biomarkers of inflammation (eg, fecal calprotectin), and require colonoscopy at 8 years from diagnosis for surveillance of dysplasia. Risk stratification by disease location (eg, Montreal Classification) and disease activity (eg, Mayo Score) can guide management of UC. First-line therapy for induction and maintenance of remission of mild to moderate UC is 5-aminosalicylic acid. Moderate to severe UC may require oral corticosteroids for induction of remission as a bridge to medications that sustain remission (biologic monoclonal antibodies against tumor necrosis factor [eg, infliximab], \u03b14\u03b27 integrins [vedolizumab], and interleukin [IL] 12 and IL-23 [ustekinumab]) and oral small molecules that inhibit janus kinase (eg, tofacitinib) or modulate sphingosine-1-phosphate (ozanimod). Despite advances in medical therapies, the highest response to these treatments ranges from 30% to 60% in clinical trials. Within 5 years of diagnosis, approximately 20% of patients with UC are hospitalized and approximately 7% undergo colectomy. The risk of colorectal cancer after 20 years of disease duration is 4.5%, and people with UC have a 1.7-fold higher risk for colorectal cancer compared with the general population. Life expectancy in people with UC is approximately 80.5 years for females and 76.7 years for males, which is approximately 5 years shorter than people without UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv230015-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>UC affects approximately 400 of every 100\u202f000 people in North America. An effective treatment for mild to moderate UC is 5-aminosalicylic acid, whereas moderate to severe UC can be treated with advanced therapies that target specific inflammation pathways, including monoclonal antibodies to tumor necrosis factor, \u03b14\u03b27 integrins, and IL-12 and IL-23 cytokines, as well as oral small molecule therapies targeting janus kinase or sphingosine-1-phosphate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2023.15389","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T11:02:48Z","timestamp":1694516568000},"page":"951","source":"Crossref","is-referenced-by-count":789,"title":["Ulcerative Colitis in Adults"],"prefix":"10.1001","volume":"330","author":[{"given":"Beatriz","family":"Gros","sequence":"first","affiliation":[{"name":"IBD Edinburgh Unit, Western General Hospital, Edinburgh, Scotland"},{"name":"Department of Gastroenterology and Hepatology, Reina Sof\u00eda University Hospital, C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilaad G.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"jrv230015r1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.gastro.2016.10.020","article-title":"Understanding and preventing the global increase of inflammatory bowel disease.","volume":"152","author":"Kaplan","year":"2017","journal-title":"Gastroenterology"},{"issue":"10080","key":"jrv230015r2","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis.","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"jrv230015r3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1053\/j.gastro.2019.01.002","article-title":"Past and future burden of inflammatory bowel diseases based on modeling of population-based data.","volume":"156","author":"Coward","year":"2019","journal-title":"Gastroenterology"},{"issue":"10114","key":"jrv230015r4","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"jrv230015r5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"issue":"3","key":"jrv230015r6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cgh.2017.06.016","article-title":"Natural history of adult ulcerative colitis in population-based cohorts: a systematic review.","volume":"16","author":"Fumery","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"jrv230015r7","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD.","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"6","key":"jrv230015r8","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s10620-021-07200-1","article-title":"Systematic review and meta-analysis: risk of hospitalization in patients with ulcerative colitis and Crohn\u2019s disease in population-based cohort studies.","volume":"67","author":"Tsai","year":"2022","journal-title":"Dig Dis Sci"},{"issue":"10","key":"jrv230015r9","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.cgh.2020.10.039","article-title":"Contemporary risk of surgery in patients with ulcerative colitis and Crohn\u2019s disease: a meta-analysis of population-based cohorts.","volume":"19","author":"Tsai","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"jrv230015r10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41575-022-00738-z","article-title":"Improving IBD outcomes in the era of many treatment options.","volume":"20","author":"Kobayashi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"jrv230015r11","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1136\/gutjnl-2019-318936","article-title":"IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology.","volume":"68","author":"Jones","year":"2019","journal-title":"Gut"},{"issue":"1","key":"jrv230015r12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease.","volume":"18","author":"Kaplan","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"45","key":"jrv230015r13","doi-asserted-by":"publisher","first-page":"E1394","DOI":"10.1503\/cmaj.190976","article-title":"Life expectancy and health-adjusted life expectancy in people with inflammatory bowel disease.","volume":"192","author":"Kuenzig","year":"2020","journal-title":"CMAJ"},{"issue":"27","key":"jrv230015r14","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases.","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med"},{"issue":"14","key":"jrv230015r15","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer biologic and small-molecule therapies for inflammatory bowel disease.","volume":"385","author":"Baumgart","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"jrv230015r16","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.crohns.2012.09.003","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis.","volume":"6","author":"Dignass","year":"2012","journal-title":"J Crohns Colitis"},{"issue":"2","key":"jrv230015r17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications.","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"3","key":"jrv230015r18","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otac016","article-title":"Impact of bowel urgency on quality of life and clinical outcomes in patients with ulcerative colitis.","volume":"4","author":"Dubinsky","year":"2022","journal-title":"Crohns Colitis 360"},{"issue":"1","key":"jrv230015r19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13017-021-00362-3","article-title":"WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting.","volume":"16","author":"De Simone","year":"2021","journal-title":"World J Emerg Surg"},{"key":"jrv230015r20","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad061","article-title":"Prevalence of extraintestinal manifestations in inflammatory bowel disease: a systematic review and meta-analysis.","author":"Kilic","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"jrv230015r21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease.","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"4","key":"jrv230015r22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/gutjnl-2020-322129","article-title":"Emerging treatment options for extraintestinal manifestations in IBD.","volume":"70","author":"Greuter","year":"2021","journal-title":"Gut"},{"issue":"4","key":"jrv230015r23","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","article-title":"The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.","volume":"96","author":"Bernstein","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"jrv230015r24","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","article-title":"Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis.","volume":"161","author":"Barberio","year":"2021","journal-title":"Gastroenterology"},{"issue":"6","key":"jrv230015r25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders.","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"55","key":"jrv230015r26","doi-asserted-by":"publisher","first-page":"xv","DOI":"10.3310\/hta17550","article-title":"Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.","volume":"17","author":"Waugh","year":"2013","journal-title":"Health Technol Assess"},{"issue":"4","key":"jrv230015r27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/ajg.2007.102.issue-4","article-title":"Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy.","volume":"102","author":"von Roon","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"jrv230015r28","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ajg.2015.6","article-title":"A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.","volume":"110","author":"Menees","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"jrv230015r29","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/ecco-jcc\/jjaa110","article-title":"ECCO position paper: harmonization of the approach to ulcerative colitis histopathology.","volume":"14","author":"Magro","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"4","key":"jrv230015r30","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/apt.2011.33.issue-4","article-title":"Systematic review: Clostridium difficile and inflammatory bowel disease.","volume":"33","author":"Goodhand","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"jrv230015r31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cgh.2016.10.024","article-title":"Management of Clostridium difficile infection in inflammatory bowel disease: expert review from the clinical practice updates committee of the AGA Institute.","volume":"15","author":"Khanna","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"jrv230015r32","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/apt.14063","article-title":"Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis.","volume":"45","author":"Roda","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"jrv230015r33","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis.","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"jrv230015r34","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","article-title":"AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis.","volume":"156","author":"Ko","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"jrv230015r35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment.","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"26","key":"jrv230015r36","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv230015r37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","article-title":"ECCO-ESGAR guideline for diagnostic assessment in IBD part 2: IBD scores and general principles and technical aspects.","volume":"13","author":"Sturm","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"1","key":"jrv230015r38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/apt.v51.1","article-title":"Systematic review with meta-analysis: mortality in acute severe ulcerative colitis.","volume":"51","author":"Dong","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"4947","key":"jrv230015r39","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis: final report on a therapeutic trial.","volume":"2","author":"Truelove","year":"1955","journal-title":"BMJ"},{"issue":"1","key":"jrv230015r40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.crohns.2014.08.012","article-title":"European evidence based consensus on surgery for ulcerative colitis.","volume":"9","author":"\u00d8resland","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"12","key":"jrv230015r41","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jama.2020.11583","article-title":"Ulcerative colitis in adults.","volume":"324","author":"Glick","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"jrv230015r42","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/apt.2013.38.issue-3","article-title":"Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation: a placebo-controlled study.","volume":"38","author":"Watanabe","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"jrv230015r43","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1053\/j.gastro.2015.01.037","article-title":"Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis.","volume":"148","author":"Sandborn","year":"2015","journal-title":"Gastroenterology"},{"issue":"8","key":"jrv230015r44","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/apt.2013.37.issue-8","article-title":"Randomised clinical trial: once- vs twice-daily prolonged-release mesalazine for active ulcerative colitis.","volume":"37","author":"Flouri\u00e9","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"jrv230015r45","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/gut.2004.060103","article-title":"Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild\/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.","volume":"54","author":"Marteau","year":"2005","journal-title":"Gut"},{"issue":"6","key":"jrv230015r46","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1053\/j.gastro.2009.08.069","article-title":"Delayed-release oral mesalamine 4.8 g\/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"issue":"8","key":"jrv230015r47","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.","volume":"8","author":"Murray","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"jrv230015r48","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1053\/j.gastro.2012.08.003","article-title":"Once-daily budesonide MMX extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"10","key":"jrv230015r49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007698.pub3","article-title":"Oral budesonide for induction of remission in ulcerative colitis.","volume":"2015","author":"Sherlock","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"jrv230015r50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/gut.2005.068809","article-title":"Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis.","volume":"55","author":"Ardizzone","year":"2006","journal-title":"Gut"},{"issue":"5","key":"jrv230015r51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000478.pub4","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.","volume":"2016","author":"Timmer","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"jrv230015r52","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease.","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"jrv230015r53","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jgh.2019.34.issue-3","article-title":"Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: A systematic review and meta-analysis.","volume":"34","author":"Huang","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"issue":"18","key":"jrv230015r54","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis.","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv230015r55","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis.","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"issue":"10292","key":"jrv230015r56","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial.","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"issue":"10341","key":"jrv230015r57","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"issue":"14","key":"jrv230015r58","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis.","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv230015r59","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40264-021-01057-z","article-title":"Safety of S1P modulators in patients with immune-mediated diseases: a systematic review and meta-analysis.","volume":"44","author":"Lasa","year":"2021","journal-title":"Drug Saf"},{"issue":"23","key":"jrv230015r60","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis.","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"jrv230015r61","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","article-title":"Infliximab-related infusion reactions: systematic review.","volume":"9","author":"Lichtenstein","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"2","key":"jrv230015r62","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"jrv230015r63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"jrv230015r64","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"8","key":"jrv230015r65","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis.","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"issue":"40","key":"jrv230015r66","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030590","article-title":"Efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.","volume":"101","author":"Qiu","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"13","key":"jrv230015r67","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis.","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv230015r68","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/ibd\/izaa236","article-title":"Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2\/3 studies.","volume":"27","author":"Sandborn","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"26","key":"jrv230015r69","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis.","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"jrv230015r70","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1046\/j.1365-2036.2000.00784.x","article-title":"Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study.","volume":"14","author":"Pokrotnieks","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"jrv230015r71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.","volume":"2016","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"jrv230015r72","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/ecco-jcc\/jjv101","article-title":"Budesonide MMX for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis.","volume":"9","author":"Lichtenstein","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"1","key":"jrv230015r73","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1053\/j.gastro.2020.08.060","article-title":"AGA clinical practice update on management of inflammatory bowel disease in elderly patients: expert review.","volume":"160","author":"Ananthakrishnan","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"jrv230015r74","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"issue":"13","key":"jrv230015r75","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis.","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv230015r76","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis.","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"jrv230015r77","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"jrv230015r78","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking through the therapeutic ceiling: what will it take?","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"issue":"10","key":"jrv230015r79","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis.","volume":"71","author":"Burr","year":"2021","journal-title":"Gut"},{"issue":"10","key":"jrv230015r80","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis.","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"jrv230015r81","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/ecco-jcc\/jjw198","article-title":"ECCO position statement on the use of biosimilars for inflammatory bowel disease: an update.","volume":"11","author":"Danese","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"4","key":"jrv230015r82","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"jrv230015r83","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/gut.38.6.905","article-title":"Predicting outcome in severe ulcerative colitis.","volume":"38","author":"Travis","year":"1996","journal-title":"Gut"},{"issue":"1","key":"jrv230015r84","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"jrv230015r85","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study.","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"jrv230015r86","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad036","article-title":"Tofacitinib for acute severe ulcerative colitis: a systematic review.","author":"Steenholdt","journal-title":"J Crohns Colitis"},{"issue":"2","key":"jrv230015r87","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/ajg.2011.386","article-title":"Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements.","volume":"107","author":"Bitton","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"jrv230015r88","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s41687-018-0049-2","article-title":"Development and validation of the ulcerative colitis patient-reported outcomes signs and symptoms (UC-pro\/SS) diary.","volume":"2","author":"Higgins","year":"2017","journal-title":"J Patient Rep Outcomes"},{"issue":"6","key":"jrv230015r89","doi-asserted-by":"publisher","first-page":"885","DOI":"10.14309\/ajg.0000000000000596","article-title":"Incorporating fecal calprotectin into clinical practice for patients with moderate-to-severely active ulcerative colitis treated with biologics or small-molecule inhibitors.","volume":"115","author":"Dulai","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"jrv230015r90","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ibd\/izx100","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses: part I.","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"jrv230015r91","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease.","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"jrv230015r92","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG clinical guideline: preventive care in inflammatory bowel disease.","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"jrv230015r93","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/MIB.0000000000000620","article-title":"Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases.","volume":"22","author":"Mikocka-Walus","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"jrv230015r94","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/MIB.0b013e31828029c0","article-title":"Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies.","volume":"19","author":"Lutgens","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"jrv230015r95","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1053\/j.gastro.2021.05.063","article-title":"AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review.","volume":"161","author":"Murthy","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"jrv230015r96","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1053\/j.gastro.2020.12.036","article-title":"Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: systematic review and meta-analysis.","volume":"160","author":"Wijnands","year":"2021","journal-title":"Gastroenterology"},{"issue":"10","key":"jrv230015r97","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/S2468-1253(21)00101-1","article-title":"Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.","volume":"6","author":"Shen","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"jrv230015r98","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00384-021-04067-6","article-title":"Prevalence of \u2018pouch failure\u2019 of the ileoanal pouch in ulcerative colitis: a systematic review and meta-analysis.","volume":"37","author":"Alsafi","year":"2022","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"jrv230015r99","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/codi.v24.1","article-title":"Prevalence of pouchitis in both ulcerative colitis and familial adenomatous polyposis: a systematic review and meta-analysis.","volume":"24","author":"Sriranganathan","year":"2022","journal-title":"Colorectal Dis"},{"issue":"5","key":"jrv230015r100","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/MEG.0000000000002362","article-title":"Network meta-analysis: efficacy of treatment for acute, chronic, and prevention of pouchitis in ulcerative colitis.","volume":"34","author":"Poo","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"jrv230015r101","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/ibd\/izz005","article-title":"The incidence and definition of Crohn\u2019s disease of the pouch: a systematic review and meta-analysis.","volume":"25","author":"Barnes","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"13","key":"jrv230015r102","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2208450","article-title":"Vedolizumab for the treatment of chronic pouchitis.","volume":"388","author":"Travis","year":"2023","journal-title":"N Engl J Med"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2809412\/jama_gros_2023_rv_230015_1694462878.63724.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T11:02:56Z","timestamp":1694516576000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2809412"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":102,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,9,12]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.15389","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,12]]}}}